The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse

Abstract Background The plasma cell malignancy multiple myeloma (MM) remains incurable due to the inevitable development of drug resistance (DR). Epigenetic modifiers are frequently mutated or deregulated in MM patients, contributing to MM progression and relapse. Overexpression of the de novo DNA m...

詳細記述

書誌詳細

主要な著者:	Catharina Muylaert, Lien Ann Van Hemelrijck, Arne Van der Vreken, Robbe Heestermans, Hatice Satilmis, Emma Verheye, Elina Alaterre, Catharina Olsen, Nathan De Beule, Kim De Veirman, Eline Menu, Karin Vanderkerken, Jérôme Moreaux, Elke De Bruyne
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2025-04-01
シリーズ:	Journal of Experimental & Clinical Cancer Research
主題:	Multiple myeloma Epigenetics DNMT3B Relapse
オンライン･アクセス:	https://doi.org/10.1186/s13046-025-03382-y
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!